Cost-Utility Analysis of Paclitaxel in Combination with Cisplatin for Patients with Advanced Ovarian Cancer

By Ortega A.   Dranitsaris G.   Sturgeon J.   Sutherland H.   Oza A.  

Gynecologic Oncology, Vol. 66, Iss. 3, 1997-09 ,pp. : 454-463

Elsevier

Access to resources Recommend Favorite

Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease - a prospective randomised trial

By van Agthoven M.   Vellenga E.   Fibbe W.E.   Kingma T.   Uyl-de Groot C.A.  

European Journal of Cancer, Vol. 37, Iss. 14, 2001-09 ,pp. : 1781-1789

Elsevier

Access to resources Recommend Favorite

Treatment of paediatric Hodgkin's disease - a balance of risks

By Thomson A.B.W.   Wallace W.H.B.  

European Journal of Cancer, Vol. 38, Iss. 4, 2002-03 ,pp. : 468-477

Elsevier

Access to resources Recommend Favorite

Survival Analysis of Patients with Clinical Stages I or II Hodgkin's Disease Who Have Relapsed After Initial Treatment with Radiotherapy Alone

By Horwich A.   Specht L.   Ashley S.  

European Journal of Cancer, Vol. 33, Iss. 6, 1997-05 ,pp. : 848-853

Elsevier

Access to resources Recommend Favorite

Treatment of refractory hodgkin’s disease with modified stanford V program

By Avilés Agustin   Neri Natividad   García Edna   Talavera Alejandra   Díaz-Maqueo José  

Medical Oncology, Vol. 18, Iss. 4, 2001-12 ,pp. : 261-267

Humana Press, Inc

Access to resources Recommend Favorite